NexImmune 8/10/2023 Earnings Report

NexImmune EPS Results

• Actual EPS: -$7.25
• Consensus EPS: -$7.25
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

NexImmune Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NexImmune Announcement Details

• Date: 8/10/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

NexImmune (NASDAQ:NEXI) is a clinical-stage biotechnology company focused on developing antigen-specific immune tolerance therapies for autoimmune and inflammatory diseases. The company’s proprietary artificial antigen-presenting cell (aAPC) platform is designed to selectively modulate immune responses by expanding regulatory T cells or deleting pathogenic T cells without the need for broad immunosuppression.

The company’s lead product candidate, NX-13, is in Phase 1 clinical development for inflammatory bowel disease. In parallel, NexImmune is advancing a diversified pipeline of preclinical programs targeting conditions such as type 1 diabetes, celiac disease and transplant rejection. Early-stage studies have demonstrated promising safety profiles and on-target activity for several of these investigational therapies.

Founded in 2013 as a spinout from the La Jolla Institute for Allergy & Immunology, NexImmune is headquartered in Gaithersburg, Maryland. The company completed its initial public offering on the Nasdaq Stock Market under the ticker symbol NEXI in 2015. Its facilities support both discovery research and the manufacturing of cell therapy materials for clinical trials.

NexImmune collaborates with academic institutions and contract research organizations across North America and Europe to advance its clinical development programs. The company is led by a management team with deep expertise in immunology, cell therapy development and biotechnology commercialization.